In vitro and in vivo studies showed that dual mTORC1/C2 inhibitor is more active against myeloma cells than mTORC1 inhibition alone (rapamycin) that could results in the feedback activation of AKT [27, 46]. The gene discussed is AKT1; the disease is plasma cell myeloma.